Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Growth Hormone and IGF Research

Volumn 9, Issue 2, 1999, Pages 106-113

  Johansen, Peter B ^a   Nowak, Jette ^a   Skjærbaek, Christian ^b   Flyvbjerg, Allan ^b   Andreassen, Troels T ^b   Wilken, Michael ^a   Orskov H ^b  

^a NOVO NORDISK A S   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

GH secretagogue; Ipamorelin; Longitudinal bone growth; Rats

Indexed keywords

ACID PHOSPHATASE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; IPAMORELIN; OSTEOCALCIN; PENTAPEPTIDE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE; BONE GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE RELEASE; HYPOPHYSIS; IMMUNOBLOTTING; INTRAVENOUS DRUG ADMINISTRATION; METAPHYSIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033136383     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.1999.9998     Document Type: Article

References (37)

1. Bowers C Y, Sartor A O, Reynolds G A, Badger T M. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991; 128: 2027-2035.
2. Pong S S, Chaung L Y, Dean D C, Nargund R P, Patchett A A, Smith R G. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996; 10: 57-61.
3. Raun K, Hansen B S, Johansen N L, Thøgersen H, Madsen K, Ankersen M, Andersen P H. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998; 139: 552-561.
4. Rasmussen M H, Søgaard B, Ynddal L, Groes L, Helmgaard L, Nordholm L:. Ipamorelin-a novel very potent growth hormone secretagogue. Growth Hormone IGF Res 1998; 8: p-11
5. Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon E, Lengerts V, Deghenghi R. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clin Endocrinol 1994; 41: 539-541.
6. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo B P, Lenhaerts V, Deghenghi R, Camanni F, Ghigo E. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab 1995; 80: 1090-1094.
7. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers C Y, Merriam G R. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH- Deficient children. J Clin Endocrinol Metab 1998; 83: 2355-2360.
8. Pihoker C, Badger T M, Reynolds G A, Bowers C Y Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 1997; 155: 79-86.
9. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995; 43: 631-635.
10. Yu H., Cassorla F, Tiulpakov A, Shi Y-F, Setin N, Bereu B, Arango A, Kletter G, Pescovitz O, Di Martino J, Krupa D, Cambria M, Kanojia P, Bach M A. A double blind placebo-controlled efficacy trial of an oral growth hormone (GH) secretagogue (MK-0677) in GH deficient (GHD) children. The 80th Annual Meeting of The Endocrine Society, New Orleans 1998; OR-24-6.
11. Isgaard J, Carlsson L, Isaksson O G, JanssonJ O. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 1988; 123: 2605-2610.
12. Isgaard J, Nilsson A, Lindahl A, Jansson J O, Isaksson O G. Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats. Amj Physiol 1986; 250: E367-E372.
13. Nilsson A, Isgaard J, Lindahl A, Peterson L, Isaksson O. Effects of unilateral arterial infusion of GH and IGF-I on tibial longitudinal bone growth in hypophysectomized rats. Calc Tissue Int 1987; 40: 91-96.
14. Bancroft JD. Theory and Practice of Histological Techniques. Edinburgh: Churchill Livingstone, 1990; 379-399.
15. Birge C A, Peake G T, Mariz I K, Daughaday W H. Radioimmunoassayable growth hormone in the rat pituitary gland: Effects of age, sex and hormonal state. Endocrinology 1967; 81: 195-204.
16. Bercu B B, Weideman C A, Walker R F. Sex differences in growth hormone (GH) secretion by rats administered GH- Releasing hexapeptide. Endocrinology 1991; 129: 2592-2598.
17. Gundberg C M, Hauschka P V, Lian J B, Gallop P M. Osteocalcin: Isolation, characterization, and detection. Methods Enzymol 1984; 107: 516-544.
18. Frystyk J, Skjaerbaek C, Dinesen B, Ørskov H. Free insulin-like growth-factors (IGF-I and IGF-II) in human serum. FEES Lett 1994; 348: 185-191.
19. Frystyk J, Gronbaek H, Skjaerbaek C, Flyvbjerg A. Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats. Am J Physiol 1995; 32: E840-E845.
20. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: Use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986; 154: 138-143.
21. Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992; 35: 589-593.
22. Hansson L I, Menander-Sellman K, Stenstrom A, Thorngren K G. Rate of normal longitudinal bone growth in the rat. Calc Tissue Res 1972; 10: 238-251.
23. Jørgensen P H, Bak B, Andreassen T T. Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone. Bone 1991; 12: 353-359.
24. Groesbeck M D, Parlow A F. Highly improved precision of the hypophysectomized female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation, and other simple modifications. Endocrinology 1987; 120: 2582-2590.
25. Lewinson D, Shenzer P, Hochberg Z. Growth hormone involvement in the regulation of tartrate-resistant acid phosphatase-positive cells that are active in cartilage and bone resorption. Calc Tissue Int 1993; 52: 216-221.
26. Nijland E A, Strasburger C J, Popp-Snijders C, van der Wal P S, van der Veen E A. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur J Endocrinol 1998; 139: 395-401.
27. Bowers C Y, Momany F A, Reynolds G A, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-1545.
28. Painson J C, Tannenbaum G S. Sexual dimorphism of somatostatin and growth hormone-releasing factor signaling in the control of pulsatile growth hormone secretion in the rat. Endocrinology 1991; 128: 2858-2866.
29. Walker R F, Bercu B B. Effects of a growth hormone-releasing peptide-like nonpeptidyl growth hormone secretagogue on physiology and function in aged rats. In: Bercu B B, Walker R F, (eds). Growth Hormone Secretagogues in Clinical Practice. New York: Marcel Dekker, 1998; 187-207.
30. Guillaume V, Magnan E, Cataldi M, Dutour A, Sauze N, Renard M, Razafindraibe H, Conte-Devoix B, Deghenghi R, Lenaerts V. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994; 135: 1073-1076.
31. Dieguez C, Foord S M, Shewring G, Edwards C A, Heyburn PJ, Peters J R, Hall R, Scanion M F. The effects of long term growth hormone releasing factor (GRF 1-40) administration on growth hormone secretion and synthesis in vitro. Biochem Biophys Res 1984; 121: 111-117.
32. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D, Nargund R, Patchett A, Hickey G. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996; 137: 5284-5289.
33. Chapman I M, Bach M A, Van Cauter E, Farmer M, Krupa D, Taylor A M, Schilling L M, Cole K Y, Skfles E H, Pezzoli S S, Hartman M L, Veldhuis J D, Gormley G J, Thorner M O. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-4257.
34. Johansen P B, Hansen T K, Andersen J V, Johansen N L. Pharmacokinetics evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998; 28: 1083-1092.
35. Jaffe C A, Ho P J, Demott-Friberg R, Bowers C Y, Barkan A L. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993; 77: 1641-1647.
36. Settembrini B P, Figueroa J M, Gallardo M R, Chiocchio S R. Growth hormone (GH) but not IGF-I secretion is stimulated in aged rats by chronic hexarelin and GHRP-6 administration. Endocr Regul 1998; 32: 17-26.
37. Van den Berghe G, Wouters P, Carlsson L, Baxter R C, Bouillon R, Bowers C Y. Leptin levels in protracted critical illness-effects of growth hormone-secretagogues and thyrotropin-releasing-hormone. J Clin Endocrinol Metab 1998; 83: 3062-3070.